• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Kadimastem – AstroRx

Background

Kadimastem is a company that is currently testing an “off-the-shelf”, clinical grade  astrocyte cell product called AstroRx®. This investigational treatment consists of  astrocytes in suspension, derived from human embryonic stem cells. Astrocytes are  neighbouring (glial) cells that provide support to motor neurons when healthy. As  of July 2023, there has been a single, phase1/2a, open label trial in 10 participants  for AstroRx®. Kadimastem announced in March 2023 that it has received IND  approval to commence a phase 2a trial for AstroRx® and that this trial will evaluate  multiple doses at 3-month intervals.

Trial Design & Results

In February 2023, the results of a phase 1/2a study for AstroRx® were published.  The open label trial involved a 3-month monitoring period followed by a single  intrathecal injection of AstroRx®. Prior to dosing, all participants began a regimen  of immunosuppressant mycophenolate mofetil (MMF) because AstroRx® is not  autologous (i.e. not generated from the patient receiving the treatment).  Participants were monitored for 6 months after dosing and then could enter a  second protocol for an additional 6 months of evaluation. Three cohorts were  planned. Cohort B received a dose with a higher concentration of AstroRx® cells  than Cohort A. The last group, Cohort C, was intended to receive multiple doses,  but was discontinued because of COVID-19 pandemic challenges.  

The primary study outcomes were safety and tolerability. Central Nervous System  (CNS) imaging was conducted at specified intervals. Secondary outcomes evaluated  efficacy, with ALSFRS-R collection as well as measures of strength. Serum  biomarkers were analyzed including creatinine, creatine, and neurofilament light  (NfL).  

During the study, 3 of the 10 participants died, although not attributed by  investigators to AstroRx®. Of documented adverse events, the most common was  post lumbar puncture headache in 50% of participants. There were also a few mild  to moderate adverse events potentially related to the immunosuppressant. 

Lab values, ECG, and physical exams showed no clinically significant changes. MRI  imaging at 6 months did not show tumours, which had been a concern because  embryonic derived cells may contribute to teratomas (a type of tumour).  

In both cohorts, at 3-months after administration of AstroRx® there was a  statistically significant slowing in the rate of ALSFRS-R decline that reverted to the  pre-treatment rate at the 6 and 12 month assessments. However, the rate of SVC  decline (a marker of breathing functionality) had a statistically significant  acceleration across both cohorts at the 3 and 12-month timepoints which is  concerning and should be explored in future studies. Hand-held dynamometry, a  measure of strength, trended towards improvement but was not statistically  significant. There was no significant effect on NfL within this study.

Summary

Kadimastem has conducted a single dose open label study of AstroRx® in 10  people, of which only 6 were followed up at the one-year timepoint. Within this  trial there were multiple protocol modifications due to the COVID-19 pandemic.  

The primary focus of the trial was safety and tolerability, although measures of  efficacy and biomarkers were evaluated as well. While there were statistically  significant reductions in the rate of decline of ALSFRS-R in both cohorts of 5 people  at 3 months post treatment, for those participants that followed up at 6 and 12  months, ALSFRS-R, those changes were lost. Additionally, the statistically significant  increase in rate of SVC decline seen post treatment is concerning. There is also the  question of whether the immunosuppressant, MMT, which was administered in  addition to AstroRx® may have effects on the disease course and may be  contributing to outcomes either positively or negatively.  

The SAC acknowledges the potential ability of healthy astrocytes to provide support  to motor neuron health. Given the very small size of the trial and the single-dose  treatment of participants with no placebo there is insufficient evidence to  determine efficacy of AstroRx® in ALS/MND currently. 

A number of messages provided by Kadimastem could raise questions from  people affected by ALS/MND. Kadimastem uses the slogan “cells to cure diseases”  and their website explains that the goals of AstroRx® treatment include “replacing  malfunctioning cells” and “restoring functionality”. Evidence has not been presented  showing that AstroRx® could replace malfunctioning cells or restore functionality in  humans. 

Caution should be taken when interpreting the results so far and should continue  until larger, properly controlled clinical trials have been completed.  

International Alliance of ALS/MND Associations
March 2024


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • BrainStorm Cell Therapeutics – NurOwn
  • Clene Nanomedicine – CNM-Au8
  • Collaborative Medicinal Development – CuATSM
  • ILB – Tikomed
  • Kadimastem – AstroRx
  • Methylcobalamin
  • Mitsubishi Tanabe Pharma America – Oral Edaravone
  • Neuronata-R/Lenzumestrocel
  • NeuroSense – PrimeC
  • Neuvivo – NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • T Regulatory Cell Therapies
  • Ulefnersen – Ionis Pharmaceuticals

  • Ali Var, Turkey

    Ali Var, Turkey

  • Jean

    Jean
    jean

  • Chen Chun-Chin

    Chen Chun-Chin

  • 727747090571358167

    727747090571358167

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Bayley, Australia

    Bayley, Australia

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Rosie Riley, Les Turner ALS Foundation, USA

    Rosie Riley, Les Turner ALS Foundation, USA

  • Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

    Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

  • Chris McCauley, Diagnosed 2015 , ALS Canada

    Chris McCauley, Diagnosed 2015 , ALS Canada

  • Philip Brindle,  MND Association,  Diagnosed 2015,  England

    Philip Brindle, MND Association, Diagnosed 2015, England

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Roxana Canova, Diagnosed 2012 ,  Asociación ELA Argentina

    Roxana Canova, Diagnosed 2012 , Asociación ELA Argentina

  • Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

    Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

  • Susan Anderson, Diagnosed 2014 , Hope Loves Company,  USA

    Susan Anderson, Diagnosed 2014 , Hope Loves Company, USA

  • Zabun Nassar, MND Association, Diagnosed 2016, England

    Zabun Nassar, MND Association, Diagnosed 2016, England

  • JP

    JP

  • Sébastien Batiot, Diagnosed 2012 , ARSLA, France

    Sébastien Batiot, Diagnosed 2012 , ARSLA, France

  • Karl Hughes, Diagnosed 2010 , IMNDA,  Ireland

    Karl Hughes, Diagnosed 2010 , IMNDA, Ireland

  • Alejandro Aquino, Diagnosed 2011 , Asociación ELA Argentina

    Alejandro Aquino, Diagnosed 2011 , Asociación ELA Argentina

  • Fabio Correia

    Fabio Correia

  • David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

    David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

  • Brian Parsons

    Brian Parsons

  • Mike Small, Motor Neurone Disease (MND) Association, UK

    Mike Small, Motor Neurone Disease (MND) Association, UK

  • Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

    Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

  • Osiel Mendoza, Diagnosed 2016 ,  ALS Therapy Development Institute, USA

    Osiel Mendoza, Diagnosed 2016 , ALS Therapy Development Institute, USA

  • Daniel Hare

    Daniel Hare

  • Leon Ryba, Asociación ELA Argentina

    Leon Ryba, Asociación ELA Argentina

  • Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

  • March of Faces Photo Submission_OLGA_ELA ARGENTINA

    March of Faces Photo Submission_OLGA_ELA ARGENTINA

  • IMG_1211

    IMG_1211

  • Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

    Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

  • Inta Grubb, Diagnosed 2014,  MND Australia

    Inta Grubb, Diagnosed 2014, MND Australia

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Hollister

    Hollister
    hollister

  • Sam Hayden-Harler, Motor Neurone Disease (MND) Association, UK

    Sam Hayden-Harler, Motor Neurone Disease (MND) Association, UK

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

    Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

  • Claudette Sturk, ALS Society of Canada

    Claudette Sturk, ALS Society of Canada
    Picture2

  • Graham Johnson, MND Australia

    Graham Johnson, MND Australia

  • unnamed

    unnamed

  • Yolanda Armendariz, Diagnosed 2017 , FYADENMAC, Mexico

    Yolanda Armendariz, Diagnosed 2017 , FYADENMAC, Mexico

  • Dick Dayton, USA

    Dick Dayton, USA

  • Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

    Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

  • Dad

    Dad

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Antonio Ventriglia,  ALS Liga Belgium,  Diagnosed 2013

    Antonio Ventriglia, ALS Liga Belgium, Diagnosed 2013

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login